Literature DB >> 9840532

Altered p53 is associated with aggressive behavior of chondrosarcoma: a long term follow-up study.

Y Oshiro1, V Chaturvedi, D Hayden, T Nazeer, M Johnson, D A Johnston, N G Ordóñez, A G Ayala, B Czerniak.   

Abstract

BACKGROUND: p53 is a major tumor suppressor gene that has been implicated in the biology of a variety of human neoplasms, including some that affect the skeleton. Recent studies based on small numbers of cases have shown that overexpression or alteration of the p53 gene is frequently present in high grade, clinically aggressive chondrosarcomas of bone. In this study, the authors addressed the relation between overexpression and alteration of the p53 gene and the clinical aggressiveness of chondrosarcoma in a large series of patients for whom long term follow-up data were available.
METHODS: The authors analyzed the expression and/or alteration of the p53 gene in 158 cases of chondrosarcoma of bone using immunohistochemistry, single-strand conformation polymorphism, and direct sequencing. They then related the findings to various clinicopathologic parameters and long term follow-up data.
RESULTS: The presence of overexpression and/or structural alterations of the p53 gene was documented in 38.1% of chondrosarcomas of bone. A statistically significant correlation was observed between overexpression or alteration of the p53 gene and both the histologic grade of the tumor and the presence of metastasis. The probability of local recurrence free, metastasis free, and overall survival was significantly higher for patients with no overexpression or alteration of p53 than for patients with p53 overexpression or alteration.
CONCLUSIONS: Overexpression or alteration of the p53 gene is an important predictor of aggressive clinical behavior in chondrosarcoma of bone.

Entities:  

Mesh:

Year:  1998        PMID: 9840532     DOI: 10.1002/(sici)1097-0142(19981201)83:11<2324::aid-cncr12>3.0.co;2-u

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

Review 1.  Genetic alterations in chondrosarcomas - keys to targeted therapies?

Authors:  Andre M Samuel; Jose Costa; Dieter M Lindskog
Journal:  Cell Oncol (Dordr)       Date:  2014-01-24       Impact factor: 6.730

Review 2.  Molecular pathology of chondroid neoplasms: part 2, malignant lesions.

Authors:  W C Bell; M J Klein; M J Pitt; G P Siegal
Journal:  Skeletal Radiol       Date:  2006-10-18       Impact factor: 2.199

3.  Bimaxillary chondrosarcoma: clinical, radiologic, and histologic correlation.

Authors:  Clark C Chen; Liangge Hsu; Jonathan L Hecht; Ivo Janecka
Journal:  AJNR Am J Neuroradiol       Date:  2002-04       Impact factor: 3.825

Review 4.  TP53 in bone and soft tissue sarcomas.

Authors:  Elizabeth Thoenen; Amanda Curl; Tomoo Iwakuma
Journal:  Pharmacol Ther       Date:  2019-07-02       Impact factor: 12.310

5.  Characterization of a new human cell line (CH-3573) derived from a grade II chondrosarcoma with matrix production.

Authors:  Silvia Calabuig-Fariñas; Rosario Gil Benso; Karoly Szuhai; Isidro Machado; José Antonio López-Guerrero; Danielle de Jong; Amando Peydró; Teresa San Miguel; Lara Navarro; Antonio Pellín; Antonio Llombart-Bosch
Journal:  Pathol Oncol Res       Date:  2012-02-15       Impact factor: 3.201

6.  Markers aiding the diagnosis of chondroid tumors: an immunohistochemical study including osteonectin, bcl-2, cox-2, actin, calponin, D2-40 (podoplanin), mdm-2, CD117 (c-kit), and YKL-40.

Authors:  Søren Daugaard; Lise H Christensen; Estrid Høgdall
Journal:  APMIS       Date:  2009-07       Impact factor: 3.205

7.  Exploration of the chondrosarcoma metabolome; the mTOR pathway as an important pro-survival pathway.

Authors:  Ruben D Addie; Yvonne de Jong; Gaia Alberti; Alwine B Kruisselbrink; Ivo Que; Hans Baelde; Judith V M G Bovée
Journal:  J Bone Oncol       Date:  2019-01-29       Impact factor: 4.072

8.  Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells.

Authors:  J G van Oosterwijk; M A J H van Ruler; I H Briaire-de Bruijn; B Herpers; H Gelderblom; B van de Water; J V M G Bovée
Journal:  Br J Cancer       Date:  2013-08-06       Impact factor: 7.640

9.  Establishment of novel human dedifferentiated chondrosarcoma cell line with osteoblastic differentiation.

Authors:  Naoko Kudo; Akira Ogose; Tetsuo Hotta; Hiroyuki Kawashima; Wenguang Gu; Hajime Umezu; Tsuyoshi Toyama; Naoto Endo
Journal:  Virchows Arch       Date:  2007-07-26       Impact factor: 4.535

10.  Chondrosarcoma of the spine: a rare case with unusual presentation.

Authors:  John Panelos; Spyridon Voulgaris; Evangelos Michos; Michael Doukas; Konstantinos Charalabopoulos; Anna Batistatou
Journal:  Diagn Pathol       Date:  2006-10-30       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.